| scholarly article | Q13442814 |
| P2093 | author name string | Yasmina Iffet Eroglu | |
| P2860 | cites work | Potential risks of pharmacy compounding | Q36767791 |
| A new perspective on canine keratoconjunctivitis sicca. Treatment with ophthalmic cyclosporine | Q37937772 | ||
| The cellular mechanisms of dry eye: from pathogenesis to treatment. | Q38108573 | ||
| Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. | Q38171801 | ||
| Characteristics of FDA drug recalls: A 30-month analysis | Q40025897 | ||
| Predictors of Discordance between Symptoms and Signs in Dry Eye Disease | Q40407061 | ||
| A comparative approach to topical cyclosporine therapy | Q41678598 | ||
| Pan-European survey of the topical ocular use of cyclosporine A. | Q42653046 | ||
| Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications | Q43482891 | ||
| Cyclosporine 2% eye drops preparation | Q45041371 | ||
| An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye. | Q46896010 | ||
| The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists. | Q50786223 | ||
| Relation between signs and symptoms of dry eye in the elderly. A population-based perspective. | Q50933029 | ||
| Utility assessment among patients with dry eye disease. | Q53379868 | ||
| Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature Review | Q26770830 | ||
| Associations between signs and symptoms of dry eye disease: a systematic review | Q26781979 | ||
| Cyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study | Q33556926 | ||
| Diagnosing the severity of dry eye: a clear and practical algorithm | Q34092386 | ||
| Ocular complications of topical, peri-ocular, and systemic corticosteroids | Q34120572 | ||
| The economic burden of dry eye disease in the United States: a decision tree analysis | Q34147677 | ||
| Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years | Q34443357 | ||
| The core mechanism of dry eye disease is inflammation | Q34510429 | ||
| Cyclosporine A delivery to the eye: A pharmaceutical challenge | Q35577456 | ||
| Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb | Q35854966 | ||
| Some issues with composite endpoints in clinical trials | Q36324876 | ||
| Long-term Natural History of Dry Eye Disease from the Patient's Perspective | Q36494967 | ||
| Clinical Response, Outbreak Investigation, and Epidemiology of the Fungal Meningitis Epidemic in the United States: Systematic Review | Q36697872 | ||
| A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments | Q36714727 | ||
| Economic and quality of life impact of dry eye symptoms in women with Sjögren's syndrome. | Q53395373 | ||
| Keratitis in Dry Eye Disease and Topical Ciclosporin A. | Q53534950 | ||
| Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. | Q53620228 | ||
| [Cyclosporine eye drops: A 4-year retrospective study (2009-2013)]. | Q53817711 | ||
| Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops | Q69674155 | ||
| Longitudinal tear study after cyclosporine in kidney transplant recipients | Q71051697 | ||
| Stability of cyclosporine 1% in artificial tears | Q71792019 | ||
| Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome | Q72418731 | ||
| Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca | Q72852578 | ||
| Secondary endpoints can be validly analyzed, even if the primary endpoint does not provide clear statistical significance | Q73964389 | ||
| The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007) | Q80347907 | ||
| The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007) | Q80347909 | ||
| Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007) | Q80347919 | ||
| [Cytotoxicity evaluation of different eyes drops with cyclosporine oral solution (Sandimmun)] | Q82929549 | ||
| Addressing multiplicity issues of a composite endpoint and its components in clinical trials | Q83944160 | ||
| Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe | Q87540607 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 1336043 | |
| P577 | publication date | 2017-08-03 | |
| P1433 | published in | Journal of market access & health policy | Q27727071 |
| P1476 | title | A comparative review of Haute Autorité de Santé and National Institute for Health and Care Excellence health technology assessments of Ikervis® to treat severe keratitis in adult patients with dry eye disease which has not improved despite treatment | |
| P478 | volume | 5 |
| Q50110517 | Therapeutic inhibitors for the treatment of dry eye syndrome. | cites work | P2860 |
Search more.